Empagliflozin: Another SGLT-2i in HFrEF armamentarium
05 Nov 2020
byRoshini Claire Anthony
Adding empagliflozin to recommended therapy in patients with heart failure with reduced ejection fraction (HFrEF) reduced the risk of HF hospitalization and slowed renal function decline, the EMPEROR-Reduced* trial showed.
Empagliflozin: Another SGLT-2i in HFrEF armamentarium
05 Nov 2020
